Therapy Areas

CEO Alex Zhavoronkov talks about the firm’s progress in AI-driven R&D, hitting the right level of drug novelty, partnering with Eli Lilly and its goal of outperforming China’s biopharma engine.

Natco has announced a 90% difference in the price of its semaglutide generic in multi-dose vials versus originator Novo Nordisk’s Ozempic pen ahead of launch tomorrow as Novo’s patents on the product expire today. Its pen will be 70% cheaper.

The approval of Wegovy HD brings a more effective version to the lower-dose version and the oral formulation, but the company has struggled to compete with obesity rival Eli Lilly.

The company announced the first Phase III data testing the GIP/GLP-1/glucagon agonist in diabetic patients, showing reductions in blood sugar and superior weight loss to Mounjaro.

Pfizer, which licensed the candidate from Valneva, said the vaccine demonstrated clinically meaningful efficacy for preventing Lyme disease, even though the study failed to accrue enough cases.

Since being taken private by B-FLEXION, Paratek has been building out its commercial portfolio and Radius’s osteoporosis drug Tymlos will advance that strategy.

Moderna will pay $950m upfront under the settlement, which lifts a significant weight off its shoulders, as investors had feared it could be on the hook for $5bn.

Albert Bourla has once again been outspoken in his criticism of Vinay Prasad’s attempts to overrule FDA staff approval recommendations for vaccines, but he was more positive about other US policy reforms.

CEO Alex Zhavoronkov talks about the firm’s progress in AI-driven R&D, hitting the right level of drug novelty, partnering with Eli Lilly and its goal of outperforming China’s biopharma engine.

sponsored

Uncover how synthetic biology, biomarkers, and GenAI are advancing ADCs - and why CROs are essential to clinical and regulatory success.

The deal, which could be worth over $2bn, looks to bolster Gilead's growing immunology franchise while also granting long-time partner Galapagos a chance at a future royalty stream.

Dizal's Zegfrovy (sunvozertinib), already approved in the US and China for the second-line treatment of NSCLC with EGFR exon 20 insertion mutations, triumphs in the WU-KONG28 Phase III study in the first-line setting.

The company announced positive Phase III data and plans to file an sNDA for Arikayce in newly diagnosed patients with MAC lung disease, a potential blockbuster indication.

Coartem Baby to be rolled out in eight African countries in the autumn.

The Swiss major’s global health chief Lutz Hegemann tells Scrip on a trip to Rwanda that being a profitable enterprise while helping to improve access to new and older therapies for those who need it most is the real measure of a successful business.

Lotilaner, the active ingredient in Tarsus’s Demodex blepharitis drug Xdemvy, showed significant ability to kill ticks in a small Phase IIa study. Analysts call the Lyme program a likely out-licensing opportunity for Tarsus.

The leadership shake-up rattled investors, coming as a surprise and one day ahead of the company’s planned fiscal 2026 half year sales and earnings release.

Catch up on the developments released in the last days of 2025, from year-end FDA approvals, complete response letters and several trial disappointments.

The company, which was on the verge of bankruptcy last year, has secured an expanded approval for Omisirge for severe aplastic anemia.

Novartis presented Phase III results for anti-BAFF/ADCC antibody ianalumab in the second-line treatment of immune thrombocytopenia but will wait for first-line data to file for approvals in 2027.

New ACC/AHA dyslipidemia treatment guidelines say prescribers should consider LDL cholesterol-lowering drugs’ costs, but Amgen and Esperion note the work they’ve done to ensure access to their products.

Newly published guidelines for treating dyslipidemia recommend testing for Lipoprotein(a), a cardiovascular disease risk factor with no treatments, but with multiple candidates in the clinic.

The guidelines give specific guidance about LDL cholesterol goals, recommending Esperion’s bempedoic acid and PCSK9 inhibitors from Amgen and Regeneron on top of statins in many cases, but evidence review concluded before Repatha’s primary prevention data.